THE EFFECTS OF TERBIUM ON THE ACCUMULATION OF CISPLATIN IN HUMAN OVARIAN-CANCER CELLS

被引:15
作者
CANADA, RG
ANDREWS, PA
MACK, KM
HAIDER, A
机构
[1] GEORGETOWN UNIV,DEPT PHARMACOL,WASHINGTON,DC 20007
[2] HOWARD UNIV,SCH LIBERAL ARTS,DEPT MATH,WASHINGTON,DC 20059
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 1995年 / 1267卷 / 01期
关键词
D O I
10.1016/0167-4889(95)00019-O
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this investigation, we report a relationship between the terbium (Tb3+) binding protein and the accumulation of cisplatin in human ovarian cancer cells. The number of Tb3+ binding sites in cisplatin-resistant C13* cells is significantly greater by 79% than those in cisplatin-sensitive 2008 cells. Exposure to Tb3+ also increased the cellular accumulation of cisplatin. The accumulation of cisplatin as a function of the Tb3+ concentration in the C13* cells (0.85%/mu M Tb3+) was significantly greater than the accumulation of cisplatin in 2008 cells with respect to Tb3+ (0.46%/mu M Tb3+). The number of Tb3+ binding sites in revertant RH4 cells was similar to that in 2008 cells. The RH4 cells were less sensitive to the stimulatory effects of Tb3+ than the C13* cells. Our results show that the Tb3+ binding protein correlates with cisplatin resistance, and the receptor binding of Tb3+ increases the accumulation of cisplatin in cisplatin-resistant cells.
引用
收藏
页码:25 / 30
页数:6
相关论文
共 50 条
  • [21] DISPOSITION OF UNCHANGED CISPLATIN IN PATIENTS WITH OVARIAN-CANCER
    REECE, PA
    STAFFORD, I
    DAVY, M
    FREEMAN, S
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (03) : 320 - 325
  • [22] INTRAPERITONEAL CISPLATIN AND CARBOPLATIN IN THE MANAGEMENT OF OVARIAN-CANCER
    MARKMAN, M
    SEMINARS IN ONCOLOGY, 1994, 21 (02) : 17 - 19
  • [23] DIFFERENTIAL CYTOTOXICITY OF METAL CHELATING-AGENTS IN CISPLATIN SENSITIVE AND RESISTANT HUMAN OVARIAN-CANCER CELLS
    NICHOLSON, DL
    MAIER, RH
    PORIES, WJ
    TRACE ELEMENTS IN MEDICINE, 1993, 10 (04): : 188 - 191
  • [24] DIFFERENCES IN CISPLATIN-DNA ADDUCT FORMATION IN SENSITIVE AND RESISTANT SUBLINES OF HUMAN OVARIAN-CANCER CELLS
    REED, E
    BEHRENS, B
    YUSPA, SH
    POIRIER, MC
    HAMILTON, T
    OZOLS, RF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 285 - 285
  • [25] TAXOL SENSITIZES HUMAN OVARIAN-CANCER CELLS TO RADIATION
    STEREN, A
    SEVIN, BU
    PERRAS, J
    ANGIOLI, R
    NGUYEN, H
    GUERRA, L
    KOECHLI, O
    AVERETTE, HE
    GYNECOLOGIC ONCOLOGY, 1993, 48 (02) : 252 - 258
  • [26] ESTABLISHMENT OF A CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINE
    KIKUCHI, Y
    MIYAUCHI, M
    KIZAWA, I
    OOMORI, K
    KATO, K
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1986, 77 (06) : 1181 - 1185
  • [27] ALLELOTYPE OF HUMAN OVARIAN-CANCER
    SATO, T
    SAITO, H
    MORITA, R
    KOI, S
    LEE, JH
    NAKAMURA, Y
    CANCER RESEARCH, 1991, 51 (19) : 5118 - 5122
  • [28] HIGH-DOSE CISPLATIN THERAPY IN OVARIAN-CANCER
    OZOLS, RF
    YOUNG, RC
    SEMINARS IN ONCOLOGY, 1985, 12 (04) : 21 - 30
  • [29] OVARIAN-CANCER - SECONDARY CISPLATIN REGIMENS AND PROGNOSTIC FACTORS
    BRUCKNER, HW
    COHEN, CJ
    KABAKOW, B
    WALLACH, R
    DEPPE, G
    RATNER, L
    BHARDWAJ, S
    GOLDBERG, JD
    REISMAN, A
    HOLLAND, JF
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 469 - 469
  • [30] SECONDARY CYTOREDUCTION FOR OVARIAN-CANCER FOLLOWING CISPLATIN THERAPY
    SEGNA, RA
    DOTTINO, PR
    MANDELI, JP
    KONSKER, K
    COHEN, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 434 - 439